Table 3. Effect of spironolactone dosage (combined 2 mg/kg/day and 4 mg/kg/day) on RAS-Fingerprint^™ analytes in 10 healthy purpose-bred Beagle dogs at baseline (combined D0 and D21) and post-treatment (combined D7 and D28) using a cross-over study design at 07:00 (T1) prior to morning dosing.

Data are presented as median (IQR) in pM/L for AngI, AngII, aldosterone, Ang1-7, Ang1-5, AngIII, AngIV, and PRA-S and as a ratio for ACE-S, AA2, and ALT-S. P value compares overall treatment to baseline.

RAS Fingerprint™ analyte	Baseline	Post-treatment	Fold Difference	P-value for baseline vs. treatment
AngI(1–10)	80.3 (50.6–127.8)	100.7 (66.4–152.3)	1.25	0.35
AngII(1–8)	37.0 (27.5–54.6)	55.1 (33.1–79.9)	1.49	0.29
Aldosterone	15.9 (8.7–41.2)	32.4 (11.1–51.7)	2.04	0.07
Ang1-7	18.0 (13.5–34.6)	29.1 (20.2–39.1)	1.61	0.34
Ang1-5	23.6 (16.4–42.5)	49 (30.8–59.4)	2.08	0.16
AngIII(2–8)	5.5 (4.1–10.5)	6.9 (4.3–11.7)	1.25	0.27
AngIV(3–8)	10.3 (6.7–18.1)	13.9 (8.0–23.9)	1.35	0.26
PRA-S	119.4 (82.9–177.9)	154.2 (98.5–233.2)	1.29	0.29
ACE-S	0.5 (0.4–0.6)	0.5 (0.5–0.6)	0	0.94
AA2	0.4 (0.2–1.0)	0.6 (0.2–1.0)	1.5	0.38
ALT-S	0.3 (0.3–0.3)	0.3 (0.3–0.4)	0	0.24